Novel tissue-pressure sensing technology using a wide-band dielectric imaging system: An in vivo study.

Contact force Dielectric imaging system Radiofrequency catheter ablation Supraventricular tachycardia Tissue pressure

Journal

Journal of cardiology
ISSN: 1876-4738
Titre abrégé: J Cardiol
Pays: Netherlands
ID NLM: 8804703

Informations de publication

Date de publication:
10 2022
Historique:
received: 12 03 2022
revised: 23 04 2022
accepted: 02 05 2022
pubmed: 7 6 2022
medline: 17 8 2022
entrez: 6 6 2022
Statut: ppublish

Résumé

A novel dielectric wide-band imaging system with tissue pressure (TP) technology provides real-time contact force (CF) monitoring using non-CF catheters. This study sought to investigate the feasibility, safety, and efficacy of ablation with TP technology. Eighty-five patients with supraventricular tachycardia (SVT) were ablated with real-time monitoring of CF by TP technology and compared with 85 patients who underwent ablation with a conventional non-TP approach. Baseline characteristics, procedural data, and TP data were analyzed in the study. Ablation applications in the TP group were then subdivided into good contact and poor contact groups according to the TP level for analysis. The TP group had a significantly shorter procedural time (16.2 ± 6.9 min vs. 19.9 ± 10.0 min, p = 0.033), shorter ablation time (334.6 ± 166.9 s vs. 391.3 ± 195.7 s, p = 0.049), and fewer mean numbers of radiofrequency catheter ablation (RFCA) deliveries (6.2 ± 3.2 vs. 7.6 ± 5.2, p = 0.047) than the non-TP group. The achieved average percentage of TP >3 g was significantly higher in the good-contact group (97.94% vs. 15.48%, p < 0.001). The median impedance decreases during RFCA in the good contact group and poor contact group were 4.10 (0.30-6.88) Ω and 2.60 (-0.05-4.98) Ω at 10 s, 4.45 (0.58-8.25) Ω and 2.88 (0.23-5.70) Ω at 20 s, and 4.67 (1.95-9.08) Ω and 2.97 (-0.26-6.33) Ω at 30 s, respectively (p < 0.05 for comparisons between categories). All patients achieved acute success, and no complications were observed. Two patients in the TP group and one patient in the non-TP group experienced recurrence during follow-up. TP-technology guided ablation of SVT is feasible, efficient, and safe.

Sections du résumé

BACKGROUND
A novel dielectric wide-band imaging system with tissue pressure (TP) technology provides real-time contact force (CF) monitoring using non-CF catheters. This study sought to investigate the feasibility, safety, and efficacy of ablation with TP technology.
METHODS
Eighty-five patients with supraventricular tachycardia (SVT) were ablated with real-time monitoring of CF by TP technology and compared with 85 patients who underwent ablation with a conventional non-TP approach. Baseline characteristics, procedural data, and TP data were analyzed in the study. Ablation applications in the TP group were then subdivided into good contact and poor contact groups according to the TP level for analysis.
RESULTS
The TP group had a significantly shorter procedural time (16.2 ± 6.9 min vs. 19.9 ± 10.0 min, p = 0.033), shorter ablation time (334.6 ± 166.9 s vs. 391.3 ± 195.7 s, p = 0.049), and fewer mean numbers of radiofrequency catheter ablation (RFCA) deliveries (6.2 ± 3.2 vs. 7.6 ± 5.2, p = 0.047) than the non-TP group. The achieved average percentage of TP >3 g was significantly higher in the good-contact group (97.94% vs. 15.48%, p < 0.001). The median impedance decreases during RFCA in the good contact group and poor contact group were 4.10 (0.30-6.88) Ω and 2.60 (-0.05-4.98) Ω at 10 s, 4.45 (0.58-8.25) Ω and 2.88 (0.23-5.70) Ω at 20 s, and 4.67 (1.95-9.08) Ω and 2.97 (-0.26-6.33) Ω at 30 s, respectively (p < 0.05 for comparisons between categories). All patients achieved acute success, and no complications were observed. Two patients in the TP group and one patient in the non-TP group experienced recurrence during follow-up.
CONCLUSION
TP-technology guided ablation of SVT is feasible, efficient, and safe.

Identifiants

pubmed: 35659157
pii: S0914-5087(22)00107-1
doi: 10.1016/j.jjcc.2022.05.004
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

319-324

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no conflict of interest.

Auteurs

Lei Ding (L)

Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Cardiovascular Institute, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China.

Sixian Weng (S)

Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Cardiovascular Institute, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China.

Hongda Zhang (H)

Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Cardiovascular Institute, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China.

Fengyuan Yu (F)

Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Cardiovascular Institute, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China.

Yingjie Qi (Y)

Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Cardiovascular Institute, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China.

Shu Zhang (S)

Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Cardiovascular Institute, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China.

Min Tang (M)

Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Cardiovascular Institute, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China. Electronic address: doctortangmin@yeah.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH